This review summarises the Prosper study of enzalutamide in men with nonmetastatic, castration-resistant prostate cancer.
A total of 1401 patients were included in the study across 32 countries and 300 centres. Commentary is provided by Associate Professor Nathan Lawrentschuk, University of Melbourne, Department of Surgery Associate Professor and consultant uro-oncologist.
Please login below to download this issue (PDF)